Hot Tech Stocks To Own For 2018

Source: ThinkstockNovember 21, 2017: The S&P 500 closed up 0.66% at 2,599.23. The DJIA closed up 0.69% at 23,591.38. Separately, the Nasdaq was up 1.06% at 6,862.48.

Tuesday was a very strong day for the major U.S. exchanges, with each major index hitting a new all-time high in the session. Crude oil was positive on the day. The S&P 500 sectors were all showing green arrows for the day. The best performing sectors were technology and health care, up 1% and 0.9%, respectively. The worst performing sectors were energy and financials, up 0.2% and 0.3%, respectively.

Crude oil was up 1.0% at $56.96.

Gold was positive 0.3% at $1,279.00.

The S&P 500 stock posting the largest daily percentage loss ahead of the close Tuesday was Signet Jewelers Limited (NYSE: SIG) which traded down about 30% at $53.20. The stocks 52-week range is $46.09 to $101.46. Volume wasover 18million versus the daily average of 1.8 million shares.

Hot Tech Stocks To Own For 2018: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) jumped as much as 14.5% today after announcing earnings after the bell yesterday. As a development-stage biotech, it wasn’t the revenue or the earnings that caused the spike, but the progression of Allnylam’s pipeline.

  • [By Lisa Levin]

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares shot up 53 percent to $114.87 after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through ribonucleic acid (RNA) interference (RNAi) therapeutics, said after Tuesday's market close that a phase 3 study called APOLLO met its primary efficacy endpoint and all secondary endpoints.

  • [By Cory Renauer]

    Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS), saw a mix of setbacks and success in 2016.

  • [By Chris Dier-Scalise]

    On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.

  • [By Ben Levisohn]

    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.

Hot Tech Stocks To Own For 2018: ARIAD Pharmaceuticals Inc.(ARIA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Healthcare shares gained around 0.73 percent in trading on Monday. Meanwhile, top gainers in the sector included Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and VCA Inc (NASDAQ: WOOF).

Hot Tech Stocks To Own For 2018: WPP plc(WPPGY)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    WPP plc (WPPGY) — Most of WPP’s public websites were rendered inaccessible after the world’s biggest advertising group said its IT systems were the focus of a suspected cyberattack. Shares traded down almost 1% in early afternoon.

Hot Tech Stocks To Own For 2018: Graham Corporation(GHM)

Advisors’ Opinion:

  • [By Monica Gerson]

    Graham Corporation (NYSE: GHM) is expected to report its quarterly earnings at $0.12 per share on revenue of $23.54 million.

    Heico Corp (NYSE: HEI) is estimated to post its quarterly earnings at $0.54 per share.

Leave a Reply

Your email address will not be published. Required fields are marked *